[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Matsumura K, Sugimura K, Uchida J, Naganuma T, Nakatani T: Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy. Int J Urol; 2003 Feb;10(2):105-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy.
  • We report a case of advanced ureteral cancer successfully treated with systemic chemotherapy combined with irradiation.
  • A 47-year-old man was diagnosed as having a right ureteral cancer at the clinical stage of T4, N2 and M1 (liver).
  • A papillary tumor was also found in the bladder and the resected specimen showed a grade 1 transitional cell carcinoma.
  • Although three cycles of methotrexate, vinblastine, pirarubicin and cisplatin (MVAC) gave partial response to the ureteral tumor, new metastases to the lung and pelvic bone were observed.
  • The patient received 50 Gy external irradiation to the pelvis, 11 cycles of paclitaxel (270 mg) and cisplatin (60-80 mg) followed by four cycles of docetaxel (100 mg) and cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Methotrexate / administration & dosage. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / radiotherapy. Vinblastine / administration & dosage
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12588609.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


2. Kaag MG, O'Malley RL, O'Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, Stifelman MD, Taneja SS, Huang WC: Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol; 2010 Oct;58(4):581-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.
  • Perioperative platinum-based chemotherapy has been proposed but requires adequate renal function.
  • OBJECTIVE: Our aim was to determine whether the ability to deliver platinum-based chemotherapy following nephroureterectomy is affected by postoperative changes in renal function.
  • The value closest to 3 mo after surgery was taken as the postoperative value (range: 2-52 wk).
  • We chose an eGFR of 45 and 60 ml/min per 1.73 m(2) as possible cut-offs for chemotherapy eligibility and compared eligibility before and after surgery using the chi-square test.
  • Using a cut-off of 60 ml/min per 1.73 m(2), 49% of patients were eligible for chemotherapy before surgery, but only 19% of patients remained eligible postoperatively.
  • Patients older than the median age of 70 yr were more likely to be ineligible for chemotherapy both pre- and postoperatively by either definition, and they were significantly more likely to have an eGFR <45 ml/min per 1.73 m(2) postoperatively, regardless of their starting eGFR.
  • These changes in renal function likely affect eligibility for adjuvant cisplatin-based therapy.
  • [MeSH-major] Antineoplastic Agents / contraindications. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / surgery. Cisplatin / contraindications. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Glomerular Filtration Rate. Humans. Male. Middle Aged. Perioperative Care. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [Cites] J Urol. 2009 Sep;182(3):900-6 [19616245.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Urol. 2000 Nov;164(5):1523-5 [11025695.001]
  • [Cites] Cancer. 2003 Apr 15;97(8 Suppl):2120-6 [12673705.001]
  • [Cites] Cancer. 2003 May 1;97(9):2180-6 [12712469.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2633-5 [12860937.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):859-66 [12944571.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2150-4 [15169801.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):844-9 [15292922.001]
  • [Cites] N Engl J Med. 2004 Sep 23;351(13):1285-95 [15385655.001]
  • [Cites] N Engl J Med. 2004 Sep 23;351(13):1296-305 [15385656.001]
  • [Cites] Urol Int. 1995;55(2):74-7 [8533199.001]
  • [Cites] Abdom Imaging. 1995 Jul-Aug;20(4):365-7 [7549745.001]
  • [Cites] Radiology. 1996 Oct;201(1):194-8 [8816543.001]
  • [Cites] J Urol. 1998 Sep;160(3 Pt 1):703-6 [9720526.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Br J Urol. 1998 Sep;82(3):366-72 [9772872.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6 [15939524.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):272-9 [16424895.001]
  • [Cites] Urology. 2006 Jul;68(1):53-7 [16806415.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):735-40 [16945768.001]
  • [Cites] BJU Int. 2006 Oct;98(4):845-8 [16978282.001]
  • [Cites] Int J Urol. 2007 Jan;14(1):26-32 [17199856.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):134-41 [17207911.001]
  • [Cites] Cancer. 2009 Mar 15;115(6):1224-33 [19156917.001]
  • [Cites] J Urol. 2000 Jan;163(1):52-5 [10604312.001]
  • (PMID = 20619530.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS461287; NLM/ PMC3677959
  •  go-up   go-down


3. Inoue T, Ohyama C, Horikawa Y, Togashi H, Matsuura S, Tsuchiya N, Satoh S, Sato K, Habuchi T, Saito S, Hoshi S, Arai Y, Kato T: [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma]. Hinyokika Kiyo; 2004 Apr;50(4):273-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
  • We report three cases with methotrexate-vinblastin-adriamycin-cisplatin (MVAC) resistant multiple liver metastases of urothelial carcinoma that responded to combination chemotherapy consisting of gemcitabine plus carboplatin (GC) with additional docetaxel (GCD) as salvage chemotherapy.
  • Case 1: A 55-year-old man underwent left nephroureterectomy for ureteral cancer (TCC, G3, pT3pN1M0).
  • Three courses of GC followed by three courses of GCD were given via intra-hepatic arterial infusion for multiple liver metastases, which appeared after adjuvant high-dose MVAC therapy.
  • Case 2: A 46-year-old man underwent radical cystectomy for locally advanced bladder cancer (TCC G3 + adenocarcinoma. pT3pN0M0).
  • Two courses of GC followed by 2 courses of GCD systemic therapies were performed for multiple liver metastases, which appeared after adjuvant high-dose MVAC therapy.
  • Case 3: A 66-year-old man received three courses of MVAC for multiple metastases of the bladder cancer (TCC, G3, > pT2), which resulted in disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Male. Methotrexate / administration & dosage. Middle Aged. Taxoids / administration & dosage. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15188623.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


Advertisement
4. Watanabe M, Hayashi T, Takamatsu M, Kamitani A, Inoue M, Morisue K, Irie S, Kaneshige T: [A clinical study of renal pelvic and ureteral cancer: prognosis and frequency of subsequent bladder cancer following surgical treatment]. Nihon Hinyokika Gakkai Zasshi; 2003 Mar;94(3):428-33
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of renal pelvic and ureteral cancer: prognosis and frequency of subsequent bladder cancer following surgical treatment].
  • PURPOSE: A retrospective investigation of patients presenting with renal pelvic and ureteral cancer was performed.
  • This study focused on the prognostic factors and frequency of subsequent bladder cancer following surgical treatment.
  • Various factors were evaluated according to survival and non-bladder cancer occurrence rates.
  • Seventeen patients exhibited renal pelvic cancer, 25 cases displayed ureteral cancer and three subjects presented with multiple cancers.
  • Eleven patients had received treatment for precedent or coexistent superficial bladder cancer by transurethral resection.
  • Pathological T factor, tumor grade and pN factor demonstrated a significant effect on survival; however, sex, age, tumor localization and incidence of subsequent bladder cancer had no influence on survival.
  • The 5-year non-bladder cancer occurrence rate was 38.8%; additionally, all subsequent bladder cancer was disclosed within three years.
  • Tumor multiplicity exclusively in the upper urinary tract significantly affected occurrence of bladder cancer.
  • T factor and tumor grade revealed no correlation to occurrence.
  • CONCLUSIONS: Adjuvant chemotherapy for prevention of clinical metastasis should be considered in cases involving pT3 or higher stage, grade 3, or in instances of pathologically confirmed lymph node metastasis.
  • The significant occurrence of subsequent bladder cancer in the case of tumor multiplicity suggested that prophylactic therapy such as intravesical BCG instillation or chemotherapy might be beneficial.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / etiology

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12710077.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Abe T, Konari S, Ogata M, Komatsu S, Satoh T: [A case of CEA-producing renal pelvic and ureteral cancer]. Hinyokika Kiyo; 2003 Feb;49(2):75-9
Genetic Alliance. consumer health - Kidney cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of CEA-producing renal pelvic and ureteral cancer].
  • We report a case of carcinoembryonic antigen (CEA)-producing renal pelvic and ureteral cancer.
  • On ultrasonography and CT scan, right hydronephrosis with the renal pelvis and ureteral tumor were detected, and he was referred to our hospital.
  • Close examination of the gastro-intestinal tract did not detect any sign of digestive tumor.
  • Right nephro-ureterectomy was performed, and the tumor was histologically diagnosed as TCC G2 > G3 pT3, and CEA was positive in the tumor cells immunohistochemically.
  • CA19-9 was also positive both in the tumor cells and normal epithelium of the renal tubules.
  • Postoperatively, multiple lung metastases developed despite chemotherapy and the patient died 4 months after surgery.
  • CEA had transiently decreased postoperatively, but then increased with lung metastases, apparently related to the state of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Carcinoma, Transitional Cell / diagnosis. Kidney Pelvis / immunology. Ureteral Neoplasms / diagnosis
  • [MeSH-minor] CA-19-9 Antigen / blood. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12696186.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 17
  •  go-up   go-down


6. Takayama T, Nagata M, Unno T, Mugiya S, Hata M, Suzuki K, Fujita K: [A clinical study of patients undergoing curative surgery for renal pelvic and ureteral cancers]. Hinyokika Kiyo; 2000 Mar;46(3):155-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of patients undergoing curative surgery for renal pelvic and ureteral cancers].
  • We retrospectively studied 30 patients who underwent curative surgery for renal pelvic and/or ureteral cancer between August 1987 and August 1998.
  • Nine patients who received adjuvant chemotherapy are alive, but 3 patients have relapsed.
  • Chemotherapy did not have a significant effect on the cause-specific survival or disease-free survival.
  • [MeSH-major] Kidney Neoplasms / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Kidney Pelvis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10806570.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


7. Tsukamoto T, Yonese J, Ishii N, Maezawa T, Fukui I: [Successful salvage chemotherapy with gemcitabine, etoposide and cisplatin for metastatic ureteral cancer: a case report]. Hinyokika Kiyo; 2002 Jul;48(7):427-30
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful salvage chemotherapy with gemcitabine, etoposide and cisplatin for metastatic ureteral cancer: a case report].
  • A 35-year-old man who had undergone nephroureterectomy and a single cycle of adjuvant MVAC chemotherapy for the left ureteral cancer was referred our clinic for the treatment of paraaortic lymph node metastases.
  • Following histologic confirmation of transitional cell carcinoma by computed tomography (CT) guided biopsy, we treated him with combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin.
  • After 5 cycles of chemotherapy complete remission was obtained.
  • Thus, we treated him with a new combination chemotherapy comprising gemcitabine, etoposide and cisplatin which was approved as a phase I study by the institutional review board.
  • Adjuvant radiotherapy of 40 Gy was given to the metastatic sites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / therapy. Deoxycytidine / analogs & derivatives. Salvage Therapy. Ureteral Neoplasms / therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Lymphatic Metastasis. Male. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229181.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Kato M, Onishi T, Hoshina A, Yabana T: Successful treatment with paclitaxel/carboplatin chemotherapy in advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125. Urol Int; 2010;84(1):116-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with paclitaxel/carboplatin chemotherapy in advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.
  • Primary adenocarcinoma of the urinary tract producing tumor markers is extremely rare.
  • We report 2 cases of advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125), which were completely resected after induction chemotherapy with paclitaxel and carboplatin.
  • Patient 1 was a 72-year-old woman with adenocarcinoma of the right renal pelvis and ureter.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / biosynthesis. CA-19-9 Antigen / biosynthesis. Carboplatin / administration & dosage. Carcinoembryonic Antigen / biosynthesis. Paclitaxel / administration & dosage. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20173382.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Yasuda Y, Tatokoro M, Yokoyama M, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K: [Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation]. Nihon Hinyokika Gakkai Zasshi; 2010 Nov;101(7):758-63
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation].
  • Computed tomography (CT) scan revealed right hydronephrosis and a slightly enhanced invasive tumor in the right lower ureter, providing a diagnosis of ureteral cancer stage cT3NOM0.
  • After three courses of combination chemotherapy consisting of gemcitabine and cisplatin (GC), one tumor completely disappeared and another achieved a partial response.
  • The patient underwent radiofrequency ablation (RFA) for the residual followed by GC chemotherapy.
  • The patient underwent RFA again followed by GC chemotherapy and then all hepatic metastases have not revealed enlargement.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Catheter Ablation. Liver Neoplasms / secondary. Neoplasms, Multiple Primary. Quality of Life. Ureteral Neoplasms / pathology. Ureteral Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lymphatic Metastasis. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174743.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Sagristani M, Caraglia M, Villa MR, Lucania A, Esposito M, Petriccione L, Improta S, Marra M, Iannaci G, Rossiello R, Mastrullo L: Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer. J Exp Clin Cancer Res; 2007 Jun;26(2):291-2
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer.
  • In this manuscript for the first time we describe the concomitant diagnosis of primary renal non-Hodgkin lymphoma (PRL) and of a papillary urothelial cancer in a patient with megaloblastic anemia.
  • PRL is a rare disease, since the kidney is one of the extranodal organs usually not containing lymphoid tissue.
  • A review of literature indicated that simultaneous diagnosis of PRL and papillary urothelial carcinoma of the urether, makes our case unique.
  • The early diagnosis of both diseases allowed the eradication of the two neoplasms by nephro-ureterecthomy and by performing subsequent systemic chemotherapy.
  • [MeSH-major] Carcinoma, Papillary / radiography. Kidney Neoplasms / radiography. Lymphoma, Non-Hodgkin / radiography. Ureteral Neoplasms / radiography
  • [MeSH-minor] Early Diagnosis. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725112.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Freiha F, Srinivas S: Invasive renal pelvis transitional cell carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4694 Background: Upper tract tumors of the renal pelvis and ureter represent a small proportion of patients with transitional cell carcinoma.
  • We report our experience with invasive renal pelvis and proximal ureter transitional cell carcinoma.
  • METHODS: All patients seen at our institution between 1995 and 2003 with renal pelvis and proximal ureter who had adequate follow up were selected.
  • Of the 37 patients, 13 were ineligible (6= distal ureters; 3=non invasive cancers; 1=urethral cancer; 1=co existing lung cancer; 2=no follow up).
  • RESULTS: The median age was 72(47-92), 2/3 of the patients were men; renal pelvis was the primary site in 21, upper ureter in 3; 13 (54%) were smokers; ten patients (42%)had bladder tumors either preceding the renal pelvis tumor or after; six (25%) of the patients had distant metastases; ten (42%) had nodal metastases;The median overall survival was 27 months.
  • In those patients without nodal metastases, the T stage determined prognosis.
  • Adjuvant chemotherapy in this small series did not have an impact on survival.
  • The overall survival of patients with distant metastases in bladder cancer varies from 9 months to 33 months depending on the performance status and visceral metastases.
  • CONCLUSIONS: The median survival of patients with metastatic renal pelvis and upper tract tumors is worse than bladder cancer.
  • Early detection and adjuvant chemotherapy may have an impact and should be studied in larger number of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG: [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun;31(3):288-91
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation].
  • OBJECTIVE: To investigate the types and therapies of malignancies in renal allograft recipients.
  • METHODS: We retrospectively analyzed the occurrence, types, and therapies of malignancies in 498 renal allograft recipients who had received operations in Peking Union Medical College Hospital from May 1986 to October 2008.
  • RESULTS: Among 498 renal allograft recipients, 18 patients (3.6% ) were diagnosed with malignancies, which included bladder cancer (n = 5), renal pyloric cancer or ureteric cancer (n = 4), leukemia or lymphoma (n = 3), hepatic cancer (n = 2), skin cancer, rectum carcinoma, pulmonary carcinoma and thymoma (n = 1 each).
  • Three patients with bladder cancer and one patient with ureteric cancer experienced recurrences 7 to 15 months after operations; among them one bladder cancer patient died.
  • One non-Hodgkin's lymphoma patient died 11 months after chemotherapy.
  • Five cases with advanced unresectable malignancies died 8 to 17 months after the diagnosis.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621511.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Yasuda K, Kawa G, Kinoshita H, Matsuda T: [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):141-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here a case of ureteral cancer in which port-site metastasis was suspected after a nephroureterectomy.
  • A tumor was found in his left renal pelvis and ureter by a computed tomographic (CT) scan.
  • The patient was diagnosed with a left upper urinary tract cancer with a clinical stage of T2N0M0.
  • The pathological diagnosis was an urothelial carcinoma, grade 2 > 3, INFbeta, pT3, pV1, pN2.
  • He received two courses of MVAC chemotherapy (methotrexate 50 mg, vinblastine 5 mg, adriamycin 50mg, cisplatin 120 mg) postoperatively.
  • Since retroperitoneal lymph node metastasis was observed three months later on a CT scan, the MVAC chemotherapy was repeated for three courses.
  • Nine months later, a tumor was found in the hypodermic beside the port-site, and a needle biopsy confirmed a metastatic urothelial carcinoma.
  • He received two courses of GP chemotherapy (gemcitabine 4,250 mg, paclitaxel 225 mg).
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Laparoscopy. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378825.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


14. Hisataki T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, Itoh N, Tsukamoto T: Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology; 2000 May;55(5):663-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for the development of bladder cancer after upper tract urothelial cancer.
  • OBJECTIVES: To determine the clinical and pathologic risk factors for initial intravesical recurrence in patients with primary renal pelvic and/or ureteral cancer and to examine the progression in the bladder in patients having high risk factors for intravesical recurrence.
  • METHODS: This study included 69 patients with renal pelvic and/or ureteral cancer.
  • We excluded patients with distant metastases, those with a short period of follow-up, and those having a previous history or concomitance of bladder cancer.
  • The exclusion criteria were chosen to avoid contamination by patients with a poor prognosis who might die of the primary cancer before bladder cancer development.
  • Multivariate analysis by Cox's proportional hazards model was used to determine what clinical and pathologic variables significantly affected the initial intravesical recurrence of cancer.
  • We also studied the stage progression of cancer that recurred in the bladder.
  • RESULTS: Initial intravesical recurrence of the cancer was found in 22 patients during a median follow-up period of 53 months (range 12 to 225).
  • The intravesical disease-free rate after upper tract urothelial cancer was 65% (rate of disease recurrence in bladder 35%) at 5 years by the Kaplan-Meier method.
  • The extent (multifocality) of the upper urinary cancer (P = 0.0038) and pathologic stage (P = 0.0409) independently influenced intravesical recurrence.
  • Age, sex, adjuvant chemotherapy, configuration of the primary tumor, primary cancer size, and pathologic grade did not affect recurrence.
  • CONCLUSIONS: The extent and pathologic stage of cancer in the upper urinary tract were significant and independent factors for initial intravesical recurrence of cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792075.001).
  • [ISSN] 0090-4295
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Gungor T, Altinkaya SO, Akbay S, Bilge U, Mollamahmutoglu L: Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review. Arch Gynecol Obstet; 2010 Mar;281(3):485-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review.
  • BACKGROUND: Cystic tumors of ovary, whether benign, borderline, or malignant may be associated with mural nodule of various types, including sarcomas, sarcoma-like mural nodules (SLMN), and foci of anaplastic carcinoma.
  • Cases of serous borderline ovarian tumor with mural nodules of mixed type are very rare.
  • Preoperative Ca-125 was 798 U/ml.
  • Adhesiolysis and de-bulking surgery were performed including bilateral pelvic, para-aortic lymphadenectomy, appendectomy and omentectomy.
  • Left ureter was found to be dilated because of the infiltration of distal part by the tumor, so distal ureteral resection and neoureterocystostomy were performed.
  • Final pathology revealed borderline serous ovarian tumor with mural nodules which were consisted of SLMNs, multiple and sharply demarcated from the adjacent tumor, and sarcomatous nodules showing infiltrative appearance in metastatic regions.
  • She had postoperative chemotherapy and follow-up is going on without metastases in her first year.
  • CONCLUSION: The existence of sarcomatous nodules combined with the SLMN necessitates a careful histologic analysis for treatment and the determination of prognosis.
  • However, too few cases of mixed type mural nodules have been published to warrant a conclusion regarding their prognosis.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597831.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


16. Parisi S, Troiano M, Corsa P, Raguso A, Cossa S, Piazzolla EE, Munafò T, Sanpaolo G, Natuno A, Maiello E: Role of external radiation therapy in urinary cancers. Ann Oncol; 2007 Jun;18 Suppl 6:vi157-61
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of external radiation therapy in urinary cancers.
  • Invasive urinary tumors are relatively rare and their treatment may cause important changes in urinary, sexual, and social functions.
  • A systematic review of external radiation therapy studies in urinary cancers has been carried out.
  • There are few controlled clinical trials using adjuvant or radical radiotherapy +/- chemotherapy in kidney, ureter, and urethra cancers; there are several reports of muscle-invasive bladder cancer using multimodality treatment: intravesical surgery and neo-adjuvant chemotherapy to radiotherapy or concomitant radiochemotherapy with organ preservation.
  • The conclusions reached for renal cancer are controversial; urethra and ureter cancers data are few and inconclusive; sufficient data now exist in literature to demonstrate that conservative management with organ preservation, for muscle-invasive bladder cancer, is a valid alternative to radical cystectomy, viewed as the gold standard.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591812.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 34
  •  go-up   go-down


17. Mizutani K, Ehara H, Yokoi S, Phuoc NB, Deguchi T, Hirose Y: Treatment-related ureteral cancer following stage II testicular seminoma. Int J Clin Oncol; 2007 Dec;12(6):469-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related ureteral cancer following stage II testicular seminoma.
  • We report two cases of left ureteral carcinoma that may have been related to prior radiotherapy and anticancer chemotherapy for stage II testicular seminoma.
  • Both patients had undergone radiotherapy (60 Gy) and cisplatin-based chemotherapy, one 17 years before the present presentation and the other 24 years earlier.
  • They underwent retroperitoneoscopy-assisted left nephroureterectomy under a diagnosis of left upper ureteral cancer, established by means of ureteroscopy and brush biopsy.
  • Recently, some investigators have reported that testicular cancer survivors are at significantly increased risk of solid tumors for at least 35 years after treatment.
  • Young patients may have a high risk of cancer when they reach an advanced age.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Neoplasms, Second Primary. Radiotherapy / adverse effects. Seminoma. Testicular Neoplasms. Ureteral Neoplasms / etiology
  • [MeSH-minor] Cisplatin / adverse effects. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):640-7 [14726503.001]
  • [Cites] J Surg Oncol. 1993 Sep;54(1):60-3 [8377508.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(5):913-9 [1447034.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):669-73 [16887293.001]
  • [Cites] Urology. 1989 Mar;33(3):185-8 [2919477.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):831-5 [7591890.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] Radiat Res. 1988 Oct;116(1):3-55 [3186929.001]
  • [Cites] J Urol. 2005 Jul;174(1):107-10; discussion 110-1 [15947588.001]
  • [Cites] Radiother Oncol. 1999 Feb;50(2):191-7 [10368043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):746-8 [12788180.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Oncology. 2000;58(1):75-82 [10644944.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1101-6 [12637477.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):415-24 [8445415.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8):1203-12; discussion 1212-21 [11236311.001]
  • (PMID = 18071867.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Fujisawa H, Takagane H, Shimosegawa K, Sakuma T: [Primary malignant lymphoma of the ureter: a case report]. Hinyokika Kiyo; 2004 Oct;50(10):721-4
Genetic Alliance. consumer health - Primary malignant lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant lymphoma of the ureter: a case report].
  • Computed tomography and retrograde pyelography revealed a soft tissue mass in the middle portion of the right ureter.
  • Urine cytology specimen from the right ureter suggested transitional cell carcinoma.
  • Under the diagnosis of right ureteral cancer, we performed right total nephro-ureterectomy, partial cystectomy.
  • The histopathological examination showed non-Hodgkin lymphoma (large B-cell type) of the ureter.
  • Our diagnosis was Clinical Stage IE of the Ann Arbor Classification.
  • The patient received only the first course of systemic chemotherapy (THP-cop), because he suffered severe thrombocytopenia in the course of the chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Ureteral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15575226.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Yamamoto H, Ueda Y, Maruyama T, Kondou N, Nojima M, Takiuchi H, Mori Y, Shima H, Kubota A: [A case of CA19-9 producing transitional cell carcinoma of the ureter]. Hinyokika Kiyo; 2003 Sep;49(9):543-5
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of CA19-9 producing transitional cell carcinoma of the ureter].
  • We report a case of CA19-9 producing urothelial carcinoma of the right ureter.
  • Magnetic resonance urography and retrograde ureterography revealed a long irregular filling defect in the right distal ureter.
  • Under the diagnosis of right ureteral tumor, we performed right total nephroureterectomy and pelvic lymphadenectomy.
  • The tumor was histologically diagnosed as grade 1 transitional cell carcinoma and pelvic lymphnodes were positive (pT1N2M0).
  • The tumor cells showed positive immunostaining for CA19-9.
  • The serum CA19-9 level was normalized after the operation and successive adjuvant chemotherapy (M-VAC 2 course).
  • In this case, the serum CA19-9 level was useful as a tumor marker.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoma, Transitional Cell / immunology. Ureteral Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598694.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


20. Matsushita M, Kawasaki Y, Okada Y: [Carcinomatous meningitis from urothelial carcinoma of bladder and ureter: case report]. Nihon Hinyokika Gakkai Zasshi; 2004 Nov;95(7):817-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinomatous meningitis from urothelial carcinoma of bladder and ureter: case report].
  • Carcinomatous meningitis from urothelial carcinoma of the bladder and ureter is rare.
  • A 77-year-old man with invasive bladder cancer and right ureter cancer had been treated with 3 courses M-VAC (methotrexate, vinblastine, epirubicin, cisplatin) chemotherapy.
  • After chemotherapy we performed radical cystectomy and right nephroureterectomy (ileal-neobladder) (TCC, G3, pT3, N0, M0).
  • Patient died 6 days after diagnosis of carcinomatous meningitis.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Meningeal Neoplasms / secondary. Meningitis / etiology. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Nephrectomy. Ureter / surgery. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624493.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


21. Takagi S, Gohji K, Iwamoto Y, Masuda H, Segawa N, Kiura H, Ueda H, Katsuoka Y: [Ureter cancer of complete double renal pelvis and ureter: a case report]. Hinyokika Kiyo; 2002 Dec;48(12):761-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureter cancer of complete double renal pelvis and ureter: a case report].
  • Intravenous pyelography, computerized tomography and magnetic resonance imaging revealed ureteral tumors of the complete left double renal pelvis and the ureter.
  • An endoscopic examination disclosed a papillary tumor from the left ureteral orifice of the lower pole of the kidney.
  • A transurethral resection of the tumor was done, and the pathological features revealed transitional cell carcinoma (PTa, grade 2).
  • A left nephroureterectomy and a partial cystectomy were also carried out; macroscopic examinations showed a non-papillary tumor on the middle portion of the left ureter originating from the upper pole of the kidney.
  • Adjuvant chemotherapy (M-VAC) was administered but discontinued because of severe side effects.
  • Dispite recurrence with retro-peritoneal lymph node metastasis, the patient is alive and again undergoing M-VAC chemotherapy 22 months after the initial surgery.
  • However, the evaluation of the chemotherapy was "no change".
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis / abnormalities. Neoplasms, Multiple Primary. Ureter / abnormalities. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urologic Surgical Procedures

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613013.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


22. Sountoulides P, Kaplan A, Kaufmann OG, Sofikitis N: Current status of metal stents for managing malignant ureteric obstruction. BJU Int; 2010 Apr;105(8):1066-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of metal stents for managing malignant ureteric obstruction.
  • Obstruction of the ureters caused by extrinsic compression from a primary tumour or retroperitoneal lymph node masses is not unusual in the course of advanced pelvic malignancies.
  • Most of the cases are of gynaecological or gastrointestinal origin, and the situation can be aggravated by peri-ureteric fibrosis, a long-term adverse event of previous chemotherapy or radiotherapy.
  • Undoubtedly upper urinary tract decompression and maintenance of ureteric patency, even as a palliative measure, is important in managing these patients.
  • Plastic stents have long been used for managing malignant ureteric obstruction, but their overall success remains limited.
  • For these reasons plastic stents have been unsuccessful for long-term maintenance of ureteric patency.
  • To overcome these limitations metal stents were introduced and recently developed in an effort to ensure better long-term patency of the obstructed ureter, fewer hospital admissions for stent change and better overall quality of life.
  • In the present review the clinical applications of different types of metal stents are discussed, with a specific focus on the latest advances and the future options for managing malignant ureteric obstruction.
  • [MeSH-major] Pelvic Neoplasms / complications. Stents. Ureteral Obstruction / therapy
  • [MeSH-minor] Humans. Prosthesis Design. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.
  • (PMID = 20067458.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


23. Chew BH, Lange D: Ureteral stent symptoms and associated infections: a biomaterials perspective. Nat Rev Urol; 2009 Aug;6(8):440-8
MedlinePlus Health Information. consumer health - Ureteral Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteral stent symptoms and associated infections: a biomaterials perspective.
  • Ureteral stents are commonly used in the field of urology, and, given their indwelling nature, are often a nidus for infection and a cause of discomfort.
  • At present, drug-eluting stents have shown the most promise for inhibiting bacterial adhesion and biofilm formation.
  • Future stent designs that maintain drainage of the kidney and ureter while minimizing inflammation and contact with the urothelium will improve patient outcomes.
  • By better understanding the basic pathways of bacterial adhesion to biomaterials, new stents and medications that target these mechanisms can be developed to eliminate bacterial adhesion and infection in patients with ureteral stents.
  • [MeSH-major] Biocompatible Materials / adverse effects. Prosthesis-Related Infections / etiology. Stents / adverse effects. Stents / microbiology. Ureteral Diseases / etiology
  • [MeSH-minor] Animals. Drug-Eluting Stents / adverse effects. Drug-Eluting Stents / microbiology. Humans. Postoperative Complications / drug therapy. Postoperative Complications / etiology. Postoperative Complications / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597512.001).
  • [ISSN] 1759-4820
  • [Journal-full-title] Nature reviews. Urology
  • [ISO-abbreviation] Nat Rev Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biocompatible Materials
  • [Number-of-references] 83
  •  go-up   go-down


24. Akil I, Kavukçu S, Inan S, Yilmaz O, Atilla P, Işlekel H, Neşe N, Müftüoğlu S: Evaluation of histologic changes in the urinary tract of hypercalciuric rats. Pediatr Nephrol; 2006 Nov;21(11):1681-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we aimed to investigate the effects of hypercalciuria on the bladder, ureters, and kidneys in rats with experimentally induced hypercalciuria.Normocalcemic hypercalciuria was induced by furosemide (60 mg/100 mL of drinking water) administration to 16-week-old male Wistar Albino rats for 14 days.
  • Calciuria (calcium/creatinine ratio, mg/mg, Ca/Cr) increased from 0.07+/-0.01 at the beginning of administration to 0.41+/-0.1 on day 14 (p=0.000).
  • The Ca/Cr ratio was 0.14+/-0.06 at the beginning of the study and 0.25+/-0.06 on day 14 in the control group rats (p=0.002 vs. the hypercalciuric group rats on day 14).
  • Bladder, ureter, and kidney specimens of the rats, dissected on the 14th day, were fixed in 10% formalin and 2.5% gluteraldehyde solutions for light and electron microscopic examination, respectively.
  • Histopathological and ultrastructural examination of the hypercalciuric rats revealed proliferation and apical cytoplasmic vacuole formation in transitional epithelial cells, mitotic activity in the intermediate cell line, vasodilatation, edema, and separation of collagen fibers in the bladder and ureter specimens.
  • Light microscopic examination of the kidney specimens revealed a lot of erythrocyte in the glomerular capillary lumen, while electron microscopy revealed vacuolization of proximal and distal tubules, tubular degeneration, interstitial edema, and vasodilatation.In this study, hypercalciuria was observed to have adverse effects on the cell architecture of the uroepithelium and disruption of the epithelial barrier of the bladder and ureters and all kidney structures, especially on the proximal epithelial cells.
  • [MeSH-major] Hypercalciuria / pathology. Kidney / pathology. Ureter / pathology. Urinary Bladder / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Nephrol. 2005 Jul;20(7):940-4 [15912382.001]
  • [Cites] Urol Res. 1990;18(3):213-7 [2204174.001]
  • [Cites] Am J Kidney Dis. 1999 Apr;33(4):761-71 [10196021.001]
  • [Cites] Pediatr Nephrol. 1998 Apr;12(3):201-5 [9630037.001]
  • [Cites] Pediatr Nephrol. 2000 Sep;14 (10-11):1011-5 [10975318.001]
  • [Cites] Braz J Med Biol Res. 2005 Apr;38(4):577-82 [15962183.001]
  • [Cites] Scand J Urol Nephrol. 2001 Apr;35(2):112-6 [11411652.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2000 Jul;9(4):349-55 [10926170.001]
  • [Cites] Am J Physiol. 1992 Apr;262(4 Pt 2):F622-30 [1566875.001]
  • [Cites] Am J Physiol. 1993 May;264(5 Pt 2):F800-7 [8498532.001]
  • [Cites] Acta Paediatr. 2001 Jun;90(6):643-8 [11440097.001]
  • [Cites] Pediatr Nephrol. 2003 Apr;18(4):394-6 [12700969.001]
  • [Cites] Semin Nephrol. 1996 Sep;16(5):458-73 [8890401.001]
  • [Cites] Pediatr Nephrol. 1999 Jun;13(5):433-7 [10412865.001]
  • [Cites] J Urol. 1996 Mar;155(3):1112-6 [8583575.001]
  • [Cites] Kidney Int. 1995 Aug;48(2):501-9 [7564119.001]
  • [Cites] Endocrinol Metab Clin North Am. 2002 Dec;31(4):1001-15, ix [12474642.001]
  • [Cites] Pediatr Nephrol. 2005 Oct;20(10):1435-8 [16047226.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 2):1008-10 [10958729.001]
  • [Cites] Pediatr Nephrol. 1996 Oct;10(5):568-72 [8897557.001]
  • [Cites] J Urol. 1994 Oct;152(4):1226-8 [8072109.001]
  • [Cites] Scan Electron Microsc. 1980;(3):379-86 [7414280.001]
  • [Cites] J Urol. 1993 Apr;149(4):893-9 [8455270.001]
  • [Cites] Ren Fail. 2000;22(5):525-34 [11041285.001]
  • [Cites] Jpn J Antibiot. 2000 Aug;53(8):582-91 [11070820.001]
  • [Cites] Turk J Pediatr. 1998 Jul-Sep;40(3):399-404 [9763904.001]
  • [Cites] Med Clin North Am. 1997 May;81(3):641-52 [9167649.001]
  • (PMID = 16924550.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Poon MC, D'Oiron R, Von Depka M, Khair K, Négrier C, Karafoulidou A, Huth-Kuehne A, Morfini M, International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group: Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost; 2004 Jul;2(7):1096-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.
  • Anecdotal reports suggest recombinant factor (rF)VIIa might be a therapeutic alternative in these situations.
  • One thromboembolic event and one blood clot in the ureter occurring in surgical patients following prolonged continuous infusion of high-dose rFVIIa and antifibrinolytic drug use have been previously reported.
  • [MeSH-major] Factor VII / therapeutic use. Recombinant Proteins / therapeutic use. Thrombasthenia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Data Collection. Drug Evaluation. Factor VIIa. Female. Hemorrhage / etiology. Hemorrhage / pathology. Humans. Infant. International Cooperation. Male. Middle Aged. Premedication. Surgical Procedures, Operative / adverse effects

  • Genetic Alliance. consumer health - Thrombasthenia.
  • Genetic Alliance. consumer health - Thrombasthenia of Glanzmann and Naegeli.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15219192.001).
  • [ISSN] 1538-7933
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / recombinant FVIIa; 9001-25-6 / Factor VII; EC 3.4.21.21 / Factor VIIa
  •  go-up   go-down


26. Wang H, Satoh M, Abe H, Sunamura M, Moriya T, Ishidoya S, Saito S, Hamada H, Arai Y: Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model. Urology; 2006 Sep;68(3):674-81
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
  • OBJECTIVES: To investigate the therapeutic effect of AxdAdB-3, a double-restricted oncolytic adenovirus harboring a mutant E1A and an E1B-55KD deletion, on human bladder cancer cell lines and the SCID mouse model of orthotopic bladder cancer.
  • METHODS: The cytopathic effects of AxdAdB-3 were evaluated in several cell lines (YTS-1, YTS-3, T24, J82, 5637) derived from human bladder or ureteral cancer and in a normal bladder mucosa-derived cell line (HCV29) with AxCAlacZ (control) or AxE1AdB (E1B-55KD-defective adenovirus) or dl922-947 (E1A-mutated adenovirus).
  • The efficacy of bladder instillation therapy with AxdAdB-3 for orthotopic bladder cancer of SCID mice was investigated.
  • RESULTS: AxdAdB-3 caused the oncolysis of bladder cancer cell lines in vitro, and it was more cytopathic than AxE1AdB or dl922-947 in the cancer cell lines.
  • Direct instillation of AxdAdB-3 into the bladder of the orthotopic model inhibited tumor growth, leading to significantly prolonged survival.
  • CONCLUSIONS: Oncolytic viral therapy delivered by instillation of AxdAdB-3 is a promising tool for treating bladder cancer.
  • [MeSH-major] Adenoviridae / genetics. Oncolytic Virotherapy / methods. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Animals. Cell Line, Tumor. Disease Models, Animal. Humans. Mice. Mice, SCID

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979729.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Ishida K, Yuhara K, Kanimoto Y: [Septic shock following intracavitary Bacillus Calmette-Guerin therapy for postcystectomy ureteral cancer]. Hinyokika Kiyo; 2004 Sep;50(9):633-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Septic shock following intracavitary Bacillus Calmette-Guerin therapy for postcystectomy ureteral cancer].
  • A 72-year-old female patient was diagnosed as having a tumor in her bladder at the department of obstetrics and gynecology.
  • Transurethral resection of bladder tumor was performed in November, 2002.
  • Chemotherapy consisting of methotrexate, adriamycin and cisplatin and bladder instillation of Bacillus Calmette-Guerin (BCG) was performed.
  • Re-biopsy revealed transitional cell carcinoma, G2, carcinoma in situ of the bladder and she received radical cystectomy with ureterocutaneostomy in June, 2003.
  • After the cystectomy, the left ureter showed signs of cancer so BCG was administered through the left ureterocutaneostomy.
  • After she was given endotoxin absorption therapy, she regained normal blood pressure and her heart rate, but was still febrile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15518130.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


28. Cho KS, Cho NH, Park SY, Cho SY, Choi YD, Chung BH, Yang SC, Hong SJ: Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma. J Korean Med Sci; 2008 Jun;23(3):434-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On univariate analysis, sex, age, concomitant bladder tumors, concomitant ureter tumors, lymphadenectomy, adjuvant chemotherapy, tumor grade, multiplicity, renal parenchymal invasion, and carcinoma in situ did not influence the disease-specific survival (p>0.05).
  • Thus, systemic adjuvant therapy should be considered in the presence of peripelvic fat invasion, even if the lymph nodes are not involved.
  • [MeSH-major] Adipose Tissue / pathology. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Pelvis. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Jun 15;94(12):3150-6 [12115347.001]
  • [Cites] J Urol. 1946 Apr;55:366-72 [21020382.001]
  • [Cites] JAMA. 1971 Nov 8;218(6):845-54 [4939530.001]
  • [Cites] J Urol. 1978 May;119(5):594-7 [660726.001]
  • [Cites] J Urol. 1980 May;123(5):629-31 [7420546.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):1919-23 [2224787.001]
  • [Cites] J Urol. 1991 Jun;145(6):1159-63 [2033684.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1773-5 [1551062.001]
  • [Cites] Urology. 1995 Dec;46(6):796-800 [7502418.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):738-43 [10505034.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1545-52 [15577672.001]
  • [Cites] J Urol. 2005 Dec;174(6):2120-3; discussion 2124 [16280740.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • (PMID = 18583879.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2526530
  •  go-up   go-down


29. Lendvay TS, Sorensen M, Cowan CA, Joyner BD, Mitchell MM, Grady RW: The evolution of vesicoureteral reflux management in the era of dextranomer/hyaluronic acid copolymer: a pediatric health information system database study. J Urol; 2006 Oct;176(4 Pt 2):1864-7
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Since Food and Drug Administration approval of Deflux, injection therapy for vesicoureteral reflux has increased.
  • Little data exist on the effect that injection therapy has had on the incidence of ureteral reimplantation and total vesicoureteral reflux procedures.
  • We used the Pediatric Health Information System database to define practice trends for vesicoureteral reflux therapy.
  • MATERIALS AND METHODS: From 2002 to 2004 we extracted data on 0 to 19-year-old patients with International Classification of Diseases-9 diagnosis codes for vesicoureteral reflux, and procedure codes for ureteral reimplantation and subureteral injection therapy.
  • RESULTS: We identified a total of 4,570 procedures performed in 1,948 patients treated with injection therapy and in 2,483 treated with reimplantation.
  • CONCLUSIONS: With the introduction of a new, minimally invasive procedure for reflux therapy the number of procedures for reflux has increased, while open surgery rates have remained stable.
  • [MeSH-major] Dextrans / administration & dosage. Hyaluronic Acid / administration & dosage. Vesico-Ureteral Reflux / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Databases, Factual. Female. Humans. Infant. Injections. Male. Ureter


30. Hermida Pérez JA, Guerra Abrante P, Hernández Guerra JS, Ochoa Urdangarain O: [Lithiasis of soft appearance within a calyceal diverticulum in the right kidney. Report of one case and therapeutic management]. Arch Esp Urol; 2004 Jan-Feb;57(1):72-5
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lithiasis of soft appearance within a calyceal diverticulum in the right kidney. Report of one case and therapeutic management].
  • [Transliterated title] Litiasis de aspecto blando, alojada en un divertículo calicial del riñón derecho. Pre- sentación de un caso y conducta terapéuti- ca.
  • OBJECTIVES: To report the case of a 28-year-old female patient carrying a lithiasis of soft appearance located within a calyceal diverticulum in the right kidney which presented clinically during pregnancy, and to comment on therapeutic management, as well as the outcome one year after conservative treatment.
  • Kidney-ureter-bladder (KUB) x-ray and intravenous urography (IVP) detected a lithiasis of soft appearance within a calyceal diverticulum in the right kidney.
  • Treatment was conservative with potassium citrate/citric acid and follow-up controls with urine culture (every 3 months) and ultrasounds (every 8 months).
  • Currently she is asymptomatic but the lithiasis persists on KUB and urine culture is positive (Escherichia coli) and receives treatment with cefuroxime 250 mg every 12 hours for 6 days and nitrofurantoin 100 mg every night for three months.
  • CONCLUSIONS: Most urinary stones located within calyceal diverticula have an asymptomatic course, treatment not being necessary.
  • IVU is an effective method for diagnosis.
  • ESWL is not an effective treatment for them, being percutaneous techniques the most suitable for a single-surgical procedure resolution of both lithiasis and pyelocalyceal diverticulum.
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Female. Humans. Kidney / pathology. Kidney / radiography. Kidney / ultrasonography. Treatment Outcome. Urinary Tract Infections / drug therapy. Urinary Tract Infections / etiology. Urography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15112876.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


31. Kaneko T, Fujita K, Homma Y: Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer. Int J Urol; 2006 Mar;13(3):294-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer.
  • A 76-year-old man received intravesical bacillus Calmette-Guérin (BCG) instillations for recurrent superficial bladder cancer.
  • He had undergone right nephroureterectomy for right renal pelvic cancer 9 months previously.
  • There was no sign of recurrent bladder cancer or ureteral cancer.
  • Most of the side-effects of intravesical BCG therapy are minor, and major adverse reactions are rare.
  • Life-threatening ureteral obstruction would be a rare complication of BCG immunotherapy.
  • Although BCG intravesical instillation after nephroureterectomy is a common practice, special care should be taken of renal function in patients with unilateral kidney during BCG therapy.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. Anuria / chemically induced. BCG Vaccine / adverse effects. Carcinoma, Transitional Cell / drug therapy. Nephrostomy, Percutaneous. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Time Factors. Tomography, X-Ray Computed. Urography

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643629.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


32. Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I: Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol; 2004 Aug;11(8):592-6
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intravesical oxybutynin chloride with hydroxypropylcellulose (HPC) (modified intravesical oxybutynin) has been reported to be effective for treatment of overactive bladder.
  • METHODS: Modified intravesical oxybutynin (5 mg/10 mL, twice a day) was applied for more than 3 years to six neurogenic overactive detrusor patients (three men and three women, average age 53.3 years) who were not satisfied with oral anticholinergic agents or the other therapy.
  • A cystometogram (CMG) was performed before, 1 week after and 3 years after the start of modified intravesical oxybutynin treatment.
  • We evaluated the patient's satisfaction of this treatment after 4 weeks and again after 3 years.
  • We compared the patients' answers before and after the therapy (excellent, good, fair, unchanged and worse).
  • RESULTS: CMG studies showed that two of six patients no longer exhibited uninhibited contraction 1 week after the treatment and that the cystocapacity of patients before, 1 week after and 3 years after the initial modified intravesical oxybutynin was 129.7 +/- 19.4, 283.5 +/- 40.4 and 286.8 +/- 38.1 mL, respectively.
  • For the evaluation of patients' satisfaction with this treatment, four patients considered the therapy excellent and one patient described it as good after both 4 weeks and after 3 years.
  • Two patients dropped out of the study; one developed left ureteral cancer (2.25 years) and the other developed ileus (1.5 years).
  • CONCLUSION: Modified intravesical oxybutynin is an effective and relatively safe option of therapy for overactive bladder patients.
  • However, this therapy requires careful observation for emergent side-effects.
  • [MeSH-major] Cellulose / administration & dosage. Cellulose / analogs & derivatives. Mandelic Acids / administration & dosage. Urinary Bladder, Neurogenic / drug therapy. Urinary Incontinence / drug therapy. Urodynamics / drug effects
  • [MeSH-minor] Administration, Intravesical. Adolescent. Aged. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Patient Satisfaction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15285747.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Mandelic Acids; 9004-34-6 / Cellulose; K9P6MC7092 / oxybutynin; RFW2ET671P / hydroxypropylcellulose
  •  go-up   go-down


33. Tinger A, Waldron T, Peluso N, Katin MJ, Dosoretz DE, Blitzer PH, Rubenstein JH, Garton GR, Nakfoor BA, Patrice SJ, Chuang L, Orr JW Jr: Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys; 2001 Dec 1;51(5):1256-63
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma.
  • PURPOSE: To retrospectively review our experience using radiation therapy as a palliative treatment in ovarian carcinoma.
  • METHODS AND MATERIALS: Eighty patients who received radiation therapy for ovarian carcinoma between 1983 and 1998 were reviewed.
  • The indications for radiation therapy, radiation therapy techniques, details, tolerance, and response were recorded.
  • A complete response required complete resolution of the patient's symptoms, radiographic findings, palpable mass, or CA-125 level.
  • The actuarial survival rates from initial diagnosis and from the completion of radiation therapy were calculated.
  • Zero to 20 cycles of a platinum-based chemotherapy regimen were delivered before irradiation (median = 6 cycles).
  • The reasons for palliative treatment were: pain (n = 22), mass (n = 23), obstruction of ureter, rectum, esophagus, or stomach (n = 12), a positive second-look laparotomy (n = 9), ascites (n = 8), vaginal bleeding (n = 6), rectal bleeding (n = 1), lymphedema (n = 3), skin involvement (n = 1), or brain metastases with symptoms (n = 11).
  • Some patients received treatment for more than one indication.
  • Treatment was directed to the abdomen or pelvis in 64 patients, to the brain in 11, and to other sites in 5.
  • Twenty-eight percent of the patients experienced a complete response of their symptoms, palpable mass, and/or CA-125 level.
  • Only 11% suffered progressive disease during therapy that required discontinuation of the treatment.
  • The 1-, 2-, 3-, and 5-year actuarial survival rates from diagnosis were 89%, 73%, 42%, and 33%, respectively.
  • CONCLUSIONS: In this series of radiation therapy for advanced ovarian carcinoma, the response, survival, and tolerance rates compare favorably to those reported for current second- and third-line chemotherapy regimens.
  • Cooperative groups should consider evaluating prospectively the use of radiation therapy before nonplatinum and/or nonpaclitaxel chemotherapy in these patients.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Ovarian Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11728685.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Wanajo I, Tomiyama Y, Tadachi M, Kobayashi M, Yamazaki Y, Kojima M, Shibata N: The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics. Urol Res; 2005 Dec;33(6):409-14
Hazardous Substances Data Bank. POTASSIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.
  • We compared the potency of a selective ureteral relaxant KUL-7211 (beta(2)/beta(3)-adrenoceptor agonist; (-)-2-[4-(2-{[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)phenyloxy]acetic acid) with those of various spasmolytics on contractions in isolated canine ureteral preparations.
  • Drug effects were evaluated on the tonic contraction induced by KCl (80 mM) and on spontaneous, 1x10(-5) M phenylephrine-, and 1x10(-6) M PGF(2alpha)-induced rhythmic contractions in isolated canine ureteral preparations using a functional experimental technique.
  • The potencies (pD(2) value) of the following drugs were compared: KUL-7211, tamsulosin (an alpha(1A/1D)-adrenoceptor antagonist), prazosin (an alpha(1)-adrenoceptor antagonist), verapamil (a Ca(2+)-channel blocker), butylscopolamine (a nonselective muscarinic antagonist), and papaverine (a phosphodiesterase inhibitor).
  • Our results suggest that in dogs, the beta(2)/beta(3)-adrenoceptor agonist KUL-7211 is the most efficacious ureteral relaxant among the spasmolytics tested against various contractions.
  • Possibly, KUL-7211 might be useful for promoting stone passage and relieving ureteral colic in urolithiasis patients.
  • [MeSH-major] Acetates / pharmacology. Adrenergic beta-Agonists / pharmacology. Parasympatholytics / pharmacology. Ureter / drug effects. Ureter / physiology
  • [MeSH-minor] Animals. Colic / prevention & control. Dinoprost / pharmacology. Dogs. Humans. In Vitro Techniques. Male. Muscle Relaxation / drug effects. Phenylephrine / pharmacology. Potassium Chloride / pharmacology. Receptors, Adrenergic, beta / classification. Receptors, Adrenergic, beta / physiology. Ureteral Diseases / prevention & control. Ureteral Obstruction / prevention & control. Urinary Calculi / drug therapy

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • Hazardous Substances Data Bank. PHENYLEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2202-5 [14634379.001]
  • [Cites] J Pharmacol Sci. 2003 Aug;92(4):411-9 [12939526.001]
  • [Cites] J Urol. 2004 Sep;172(3):1155-9 [15311061.001]
  • [Cites] Br J Urol. 1987 May;59(5):396-400 [3297230.001]
  • [Cites] Acta Med Scand Suppl. 1974;559:1-26 [4526415.001]
  • [Cites] J Urol. 2001 Sep;166(3):1083-7 [11490303.001]
  • [Cites] Eur J Pharmacol. 1998 Jul 10;352(2-3):269-78 [9716364.001]
  • [Cites] J Urol. 1985 May;133(5):884-7 [3989931.001]
  • [Cites] Br J Urol. 1988 Jan;61(1):19-26 [3422576.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jan;292(1):67-75 [10604932.001]
  • [Cites] J Urol. 1996 Jul;156(1):276-80 [8648822.001]
  • [Cites] J Urol. 2000 Oct;164(4):1364-70 [10992416.001]
  • [Cites] Urology. 2000 Oct 1;56(4):575-8 [11018607.001]
  • [Cites] Urol Int. 1995;55(4):202-4 [8588266.001]
  • [Cites] Pharmacol Res Commun. 1984 Aug;16(8):765-74 [6494219.001]
  • [Cites] J Urol. 2004 Aug;172(2):568-71 [15247732.001]
  • (PMID = 16133579.001).
  • [ISSN] 0300-5623
  • [Journal-full-title] Urological research
  • [ISO-abbreviation] Urol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acetates; 0 / Adrenergic beta-Agonists; 0 / KUL7211; 0 / Parasympatholytics; 0 / Receptors, Adrenergic, beta; 1WS297W6MV / Phenylephrine; 660YQ98I10 / Potassium Chloride; B7IN85G1HY / Dinoprost
  •  go-up   go-down


35. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF: Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int; 2006 Dec;98(6):1176-80
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
  • PATIENTS AND METHODS: The records of patients who had a nephroureterectomy for UUT-TCC at our institution from 1986 to 2004 were reviewed for clinical, pathological and treatment period data.
  • Significant prognosticators for disease-specific survival (DSS) by univariate analysis were tumour stage (P < 0.01), tumour grade (P < 0.01), node-positive disease (P < 0.01), multifocality (P = 0.03), previous cystectomy (P < 0.01) and synchronous bilateral UUT-TCC (P = 0.02).
  • On multivariate analysis, only tumour stage (P = 0.03) and grade (P = 0.01) correlated with DSS.
  • The evaluation of treatment outcome during three periods of the study showed no significant effect on DSS.
  • CONCLUSION: Tumour stage and grade correlated with DSS in this cohort, with no improvement in outcome over the 18-year period assessed.
  • Patients with high-stage and high-grade disease continue to fare poorly, suggesting a need for changing the treatment protocol.
  • Judiciously applying a multimodal approach to the management of high-risk patients by incorporating neoadjuvant chemotherapy and surgical resection might provide, for the first time, the opportunity to improve patient outcome.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local / surgery. Neoplasm Staging / methods. Prognosis. Treatment Outcome. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Apr;51(4):1141-2 [17415912.001]
  • (PMID = 17125474.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846; United States / NCI NIH HHS / CA / T32 CA079449-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


36. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF: Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology; 2006 Mar;67(3):518-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anderson Cancer Center from 1990 to 2004 to identify patients with primary nonurothelial tumors of the upper urinary tract.
  • We reviewed the patient records to collect data on tumor subtype, treatment, recurrence, and survival.
  • The tumors were located in the renal pelvis in 10 and the ureter in 6.
  • Of the 16 patients, 15 had been treated with nephrectomy or nephrouterectomy and 1 with chemotherapy and radiotherapy.
  • Ten patients received adjuvant chemotherapy.
  • The median follow-up was 30.1 months, the median overall survival time was 11.3 months, and 1-year survival rate was 46%.
  • The median recurrence-free survival time and 1-year recurrence-free survival rate were 5.8 months and 38%, respectively.
  • CONCLUSIONS: Primary nonurothelial carcinomas of the renal pelvis and ureter are rare.
  • Our analysis suggests a poor prognosis for most patients with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527570.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79449; United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G: The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol; 2010 Oct;58(4):574-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center.
  • BACKGROUND: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious.
  • OBJECTIVE: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC.
  • Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded.
  • Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor.
  • RESULTS AND LIMITATIONS: Median follow-up for survivors was 48 mo.
  • Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p=0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p=0.18).
  • On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p=0.2).
  • CONCLUSIONS: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):612-8 [19075275.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):794-802 [18207313.001]
  • [Cites] J Urol. 2009 Nov;182(5):2177-81 [19758662.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):438-44 [16115524.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Urology. 1997 Sep;50(3):321-9 [9301692.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 2009 Mar 15;115(6):1224-33 [19156917.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Urol. 2009 Sep;182(3):894-9 [19616243.001]
  • [Cites] Eur Urol. 2010 Jun;57(6):1072-9 [19619934.001]
  • [Cites] J Urol. 2000 Nov;164(5):1523-5 [11025695.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • [CommentIn] Eur Urol. 2011 Apr;59(4):e23 [21255908.001]
  • [CommentIn] Eur Urol. 2011 Jan;59(1):e2 [20980096.001]
  • [CommentIn] J Urol. 2011 Feb;185(2):463 [22088622.001]
  • (PMID = 20637540.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS628548; NLM/ PMC4174409
  •  go-up   go-down






Advertisement